Tumor Necrosis Factor - Alpha inhibitor update: Adalimumab  

Oleh:

Vasoo, Sheila

Jenis: Article from Bulletin/Magazine - ilmiah internasional
Dalam koleksi: Medical Progress vol. 36 no. 02 (Feb. 2009), page 79.

Ketersediaan

Perpustakaan FK Nomor Panggil: M36.K.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The arrival of biological agents has dramatically changed the outlook of various immune-mediated inflammatory conditions. Tumour necrosis factor - alpha (TNF-alpha) is a pro-inflammatory cytokine that has acritical role in the pathogenesis of these diseases with resultant damage in cartilage, bone and bowel mucosa. TNF-alpha inhibition often leads to significant clinical improment. This review focuses on adalimumab (Humira ), one of the three licensed TNF-alpha inhibitors

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali